NICE recommends Tasigna and Gleevec for first-line CML treatment


According to final draft guidance, the UK's NICE has recommended both Tasigna (nilotinib) as well as Gleevec (imatinib) for the treatment of chronic myeloid leukemia (CML).

NICE determined that both drugs were equally as effective in the treatment of CML, leading them to make the recommendation despite there allegedly being no direct, head-to-head studies.

Novartis, maker of both drugs, will provide them to NICE as a discounted price that has remained confidential.

While NICE recommends both of the Novartis drugs for CML, they have gone on record as not recommending Bristol-Myers Squibb's CML drug, Sprycel (dasatinib).

Source: Therapeutics Daily

LymphomaInfo Social